A new era of cancer care — detecting recurrence before it happens.

Even after completing cancer treatment, a small number of cancer cells may remain in the body — a condition known as MRD (Minimal Residual Disease).
The MRD Detection Test uses advanced genetic analysis to identify trace amounts of tumor-derived DNA that cannot be detected by conventional imaging or tumor marker tests.

At Tokyo Ginza Wellness & Aging Clinic, we use MRD testing for recurrence prediction, treatment effectiveness assessment, and post-treatment monitoring, enabling highly precise, personalized oncology care.

What is MRD Detection?

The MRD Detection Test identifies trace amounts of tumor-derived DNA (ctDNA: circulating tumor DNA) that remain in the body after treatment, allowing early detection of residual cancer.
This next-generation monitoring method is gaining global attention for its role in evaluating recurrence risk and treatment response after therapy.

Recommended for patients who:

• Have completed surgery, chemotherapy, or radiation therapy and are concerned about recurrence
• Wish to objectively confirm the effectiveness of their treatment
• Want to monitor their condition at the molecular level after treatment
• Seek to quantify their cancer risk and prepare proactively for the future

Benefits of MRD Detection Testing

Early Prediction of Recurrence Risk

Detects signs of recurrence earlier than conventional imaging methods.

Visualization of Treatment Effectiveness

Evaluates the effectiveness of surgery, chemotherapy, or immunotherapy at the molecular level.

Post-Treatment Monitoring

Continuously monitors minimal residual disease after treatment to help prevent recurrence.

Guidance for Personalized Therapy

When recurrence is predicted, treatment strategies are reconstructed based on each patient’s genetic profile to ensure optimal care.

Features of MRD Detection at Our Clinic

• Integrated Analysis with Cancer Genomic Data

  By combining MRD testing with Comprehensive Genomic Profiling (CGP), we comprehensively evaluate genetic mutations, molecular abnormalities, and the presence or absence of residual disease. This approach minimizes the risk of oversight and allows for a more precise and personalized treatment strategy.

• Post-Treatment Follow-Up

  Regular MRD testing after treatment enables early detection of recurrence indicators. If the likelihood of recurrence increases, early intervention—such as reintroducing immunotherapy or targeted molecular therapy—will be considered.
  This proactive approach makes preventive oncology possible even before recurrence occurs.

• High-Sensitivity Detection of Trace DNA

  Using advanced digital PCR and next-generation sequencing (NGS) technologies, we can detect trace amounts of tumor-derived DNA that are undetectable by conventional blood tests.
  This high-precision method allows cancer presence to be predicted from as little as 1 mL of blood.

MRD Test Fees

This service is provided as a self-pay medical service and is not covered by health insurance.

Note: The displayed rates apply to members residing in Japan who hold a health insurance card (My Number Card).

Those without these documents will be charged the non-member rate.

• Guardant Reveal

  Test Fees

  Initial test	643,500Yen
  Subsequent tests	544,500Yen

  Guardant Reveal is a test designed for colorectal, lung, and breast cancers, and can be used to assess the risk of recurrence and to monitor for recurrence after treatment. If ctDNA is detected by Guardant Reveal, it is considered to indicate a potentially higher risk of recurrence and may serve as a reference for selecting more appropriate treatment options.

• Guardant Shield

  Test Fees

  Single test	470,250Yen

  Guardant Shield is a colorectal cancer–specific test that detects circulating tumor DNA (ctDNA) derived from colorectal cancer in the blood, similar to Guardant Reveal. It is designed to identify colorectal cancer signals with high accuracy (sensitivity: 86–94%, specificity: 92%).

The MRD (Minimal Residual Disease) detection test represents an evolution in cancer care—from “treating recurrence” to “preventing recurrence.”

As an essential component in achieving relapse prevention, early intervention, and long-term survival, the MRD test plays a crucial role in supporting our clinic’s personalized oncology program.

Rather than marking the “end” of cancer treatment, it serves as a bridge to “the next stage of reassurance.” By uncovering previously unseen risks, this test paves the way toward forward-looking cancer care that enriches patients’ lives.